gyrB Family assigned · medium auto-curated

H37Rv Rv0005 · MTBC0 mtbc0_000005 · 675 aa · 5240–7267 MTBC0 (+) · RefSeq NP_214519.2

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)DNA gyrase subunit B
MTBC0 PGAP re-annotationDNA topoisomerase (ATP-hydrolyzing) subunit B
Revised (this work)DNA topoisomerase (ATP-hydrolyzing) subunit B. Pfam: HATPase_c (PF02518.32), DNA_gyraseB (PF00204.32), Toprim (PF01751.29), DNA_gyraseB_C (PF00986.27).
Functional category (TubercuList)information pathways

Curation note: P16.23 (phase135, 2026-08-17): couche tss ajoutee (leaderless=False). P49.1 (phase233, 2026-09-15): couche tss re-clee (leaderless=False).

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 390 publications

390 TB publications mention this gene. 390 publications discuss this gene. Queried separately, 321 records carry a M. tuberculosis context and 70 a non-TB mycobacterial context (species named in the 40-record verified sample: M. abscessus (19), M. leprae (11), M. smegmatis (7), M. marinum (4)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

Full-text-only mention found (Europe PMC), not visible to the title/abstract sweep above.

Enrichment pass (not a full re-read): the wave-1/2 triage already recorded this claim as identity_claim=yes with reasoning that shares specific technical vocabulary with this atlas's own function assignment (gyrB). Treated as corroborating, not as new evidence changing the verdict.

CORROBORATES existing atlas assignment (lexical cross-check, wave1/2 enrichment pass, not independently re-read in full).

Lighter-weight than the dark-gene deep-dive protocol (phase141-151): no tbmonitor/fullTextXML re-read performed here, only a lexical consistency check against the pre-existing triage reasoning. Sufficient for an already-functional gene (enrichment), not for resolving a hypothetical.

Europe PMC full-text sweep (P16.2a-septies, phase138, vagues 1/2), passe d'enrichissement en masse (phase152, 2026-08-18) : corroboration etablie par chevauchement LEXICAL entre le raisonnement du triage initial et la fonction deja assignee dans l'atlas -- PAS une relecture integrale du papier (protocole delibere plus leger que le deep-dive dark, proportionne a une tache d'enrichissement de gene deja fonctionnel, pas de resolution d'un hypothetical).

5 of 390: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Genetic surveillance of first- and second-line drug-resistant isolates of Mycobacterium tuberculosis in Peru. doi:10.1371/journal.pone.0352881 2026
Rapid Detection of Resistance Mutations in Multidrug-Resistant Tuberculosis With GenoType MTBDRsl Assay. doi:10.1155/pm/6993694 2026
Assessing Corynebacterium glutamicum as a surrogate of Mycobacterium tuberculosis for DNA gyrase inhibitor design. doi:10.64898/2026.06.24.734172 2026
Gemifloxacin resistance in Mycobacterium tuberculosis without QRDR mutations in gyrA or gyrB: evidence for non-canonical resistance mechanisms. doi:10.1128/spectrum.03710-25 2026
Fluoroquinolones as the linchpin of tuberculosis therapy: contrasting efficacy and resistance profiles in Mycobacterium tuberculosis versus Mycobacterium abscessus. doi:10.3389/fcimb.2026.1833650 2026
376 records returned by the alias sweep (a separate sweep from the 390 above; both are shown, neither is exhaustive)

Searched as: Rv0005, gyrB, Mb0005, ML0005, MMAR_0005, MSMEG_0005, MAB_0006 — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
Identification of novel DNA gyrase B inhibitors in Mycobacterium species using integrated computational approaches. doi:10.3389/ftubr.2026.1854329 Front Tuberc 2026
Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis. doi:10.3389/fcimb.2026.1881444 Front Cell Infect Microbiol 2026
Genetic surveillance of first- and second-line drug-resistant isolates of Mycobacterium tuberculosis in Peru. doi:10.1371/journal.pone.0352881 PLoS One 2026
Rapid Detection of Resistance Mutations in Multidrug-Resistant Tuberculosis With GenoType MTBDRsl Assay. doi:10.1155/pm/6993694 Pulm Med 2026
Assessing Corynebacterium glutamicum as a surrogate of Mycobacterium tuberculosis for DNA gyrase inhibitor design. doi:10.64898/2026.06.24.734172 bioRxiv 2026
Gemifloxacin resistance in Mycobacterium tuberculosis without QRDR mutations in gyrA or gyrB: evidence for non-canonical resistance mechanisms. doi:10.1128/spectrum.03710-25 names it Microbiol Spectr 2026
Fluoroquinolones as the linchpin of tuberculosis therapy: contrasting efficacy and resistance profiles in Mycobacterium tuberculosis versus Mycobacterium abscessus. doi:10.3389/fcimb.2026.1833650 Front Cell Infect Microbiol 2026
Assessing fluoroquinolone resistance in Mycobacterium tuberculosis using nanopore sequencing: concordance with established diagnostic methods. doi:10.1007/s15010-026-02798-8 Infection 2026
Exploring Novel Gene Mutations Associated with Fluoroquinolone Resistance in Mycobacterium tuberculosis: Gene Sequencing Results from 275 Clinical Isolates in Chongqing, China. doi:10.2147/IDR.S590990 Infect Drug Resist 2026
Genomic investigation of Mycobacterium bovis in bulk unpasteurized dairy products in Ardabil Province, Iran. doi:10.1038/s41598-026-47419-4 Sci Rep 2026
Frequency, genetic mechanisms and factors associated with fluoroquinolone (pre-XDR) and aminoglycoside resistance among multidrug-resistant tuberculosis cases in Northwestern Nigeria. doi:10.1186/s12879-026-13191-z BMC Infect Dis 2026
First report of fatal feline pulmonary tuberculosis caused by the emerging zoonotic pathogen Mycobacterium orygis in a cat from India. doi:10.1007/s11259-026-11115-5 Vet Res Commun 2026
In Vitro Activity of Zoliflodacin Against Neisseria gonorrhoeae Isolates from Shanghai, China (2020-2023). doi:10.3390/antibiotics15010061 Antibiotics (Basel) 2026
Molecular modelling and structure-activity relationship of pyrrolo[2,3-d]pyrimidine derivatives as potent DNA gyrase B inhibitors. doi:10.1080/07391102.2025.2597995 J Biomol Struct Dyn 2026
Machine learning approaches to predict drug resistance in tuberculosis. doi:10.1016/j.compbiolchem.2025.108705 Comput Biol Chem 2026
Artificial intelligence for screening drug resistance in tuberculosis. doi:10.25259/IJMR_1546_2025 Indian J Med Res 2025
A novel one-tube nested fluorescence melting curve analysis for rapid detection of drug-resistant Mycobacterium tuberculosis. doi:10.1186/s12866-025-04601-4 BMC Microbiol 2025
Fluoroquinolone and Second-Line Injectable Resistance Among Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates: A Molecular Study from a High-Burden Setting. doi:10.3390/microorganisms13112470 Microorganisms 2025
Indole-containing inhibitors with improved efficacy targeting the gyrase of Mycobacterium tuberculosis. doi:10.1093/narmme/ugae027 NAR Mol Med 2025
Succinylation of GyrB Is a Mechanism Conferring Fluoroquinolone Resistance. doi:10.1021/acsinfecdis.5c00781 names it ACS Infect Dis 2025
Mutations in gyrA and gyrB among drug-resistant Mycobacterium tuberculosis isolates in South Korea. doi:10.1016/j.meegid.2025.105849 names it Infect Genet Evol 2025
Antimicrobial susceptibility patterns and genotypic characteristics of Mycobacterium marinum and Mycobacterium abscessus isolated from cutaneous infections: A retrospective study. doi:10.1016/j.jgar.2025.10.001 J Glob Antimicrob Resist 2025
Deciphering the Role of pafBC in Mycobacteriophage Resistance and Biofilm Formation. doi:10.1021/acsinfecdis.5c00627 ACS Infect Dis 2025
Genomic insights into pyrazinamide and fluoroquinolone resistance in multidrug-resistant tuberculosis in Khyber Pakhtunkhwa, Pakistan. doi:10.1016/j.ijmm.2025.151674 Int J Med Microbiol 2025
Diagnostics and new treatment regimens for TB: can the Xpert MTB/XDR assay fill the gap for fluoroquinolone testing? doi:10.1128/jcm.00643-25 J Clin Microbiol 2025
Computational analysis of Phanera sirindhorniae flavonoids as potential inhibitors of Mycobacterium tuberculosis DNA gyrase ATPase. doi:10.1016/j.compbiomed.2025.110991 Comput Biol Med 2025
Discovery of Putative GyrB Inhibitors against Mycobacterium tuberculosis: A Combined Virtual Screening and Experimental Study. doi:10.2174/0109298673374736250527040516 names it Curr Med Chem 2025
An exploratory study on the application of nanopore sequencing for detecting Mycobacterium tuberculosis drug resistance in respiratory specimens. doi:10.1186/s12890-025-03747-1 BMC Pulm Med 2025
The mutant selection window of moxifloxacin and bedaquiline resistant Mycobacterium tuberculosis. doi:10.1016/j.jinf.2025.106523 J Infect 2025
Classic and new candidate markers for drug resistance in a large cohort of leprosy patients from the Amazon state, Brazil. doi:10.1128/aac.01550-24 Antimicrob Agents Chemother 2025
Detection of a Mixed-Strain Infection with Drug- and Multidrug-Resistant Mycobacterium avium Subspecies hominissuis in a Dog with Generalized Lymphadenomegaly. doi:10.3390/antibiotics14040416 Antibiotics (Basel) 2025
Multi-drug resistance and compensatory mutations in Mycobacterium tuberculosis in Vietnam. doi:10.1111/tmi.14104 Trop Med Int Health 2025
Elucidating specific interactions for designing novel pyrrolamide derivatives as potential GyrB inhibitors based on ab initio fragment molecular orbital calculations. doi:10.1080/07391102.2023.2291178 names it J Biomol Struct Dyn 2025
Genetic diversities and drug resistance in Mycobacterium bovis isolates from zoonotic tuberculosis using whole genome sequencing. doi:10.1186/s12864-024-10909-8 BMC Genomics 2024
New generation fluoroquinolone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant Mycobacterium tuberculosis. doi:10.1099/jmm.0.001825 J Med Microbiol 2024
Ligand-Based Virtual Screening for Discovery of Indole Derivatives as Potent DNA Gyrase ATPase Inhibitors Active against Mycobacterium tuberculosis and Hit Validation by Biological Assays. doi:10.1021/acs.jcim.4c00511 J Chem Inf Model 2024
Evaluation of genetic correlation with fluoroquinolones resistance in rifampicin-resistant Mycobacterium tuberculosis isolates. doi:10.1016/j.heliyon.2024.e31959 Heliyon 2024
Signal Propagation in the ATPase Domain of Mycobacterium tuberculosis DNA Gyrase from Dynamical-Nonequilibrium Molecular Dynamics Simulations. doi:10.1021/acs.biochem.4c00161 Biochemistry 2024
Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center. doi:10.1371/journal.pone.0301210 PLoS One 2024
Identification of novel resistance-associated mutations and discrimination within whole-genome sequences of fluoroquinolone-resistant Mycobacterium tuberculosis isolates. doi:10.1128/spectrum.03930-23 Microbiol Spectr 2024
Revealing the Interaction Mechanism between Mycobacterium tuberculosis GyrB and Novobiocin, SPR719 through Binding Thermodynamics and Dissociation Kinetics Analysis. doi:10.3390/ijms25073764 names it Int J Mol Sci 2024
Efflux pump effects on levofloxacin resistance in Mycobacterium abscessus. doi:10.1128/aac.01348-23 Antimicrob Agents Chemother 2024
Recent dynamics in Neisseria gonorrhoeae genomic epidemiology in Brazil: antimicrobial resistance and genomic lineages in 2017-20 compared to 2015-16. doi:10.1093/jac/dkae075 J Antimicrob Chemother 2024
Identification and molecular characterization of Mycobacterium bovis DNA in GeneXpert® MTB/RIF ultra-positive, culture-negative sputum from a rural community in South Africa. doi:10.1016/j.onehlt.2024.100702 One Health 2024
Resolving the polycistronic aftermath: Essential role of topoisomerase IA in preventing R-loops in Leishmania. doi:10.1016/j.jbc.2024.107162 J Biol Chem 2024
Genetic stability of Mycobacterium abscessus during antibiotic treatment. doi:10.1016/j.jgar.2023.12.004 J Glob Antimicrob Resist 2024
Single-tube protocol for culture-independent spoligotyping of Mycobacterium tuberculosis based on MeltArray. doi:10.1128/jcm.01183-23 J Clin Microbiol 2024
The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data. doi:10.1016/j.jiph.2023.11.018 J Infect Public Health 2024
Computational investigation of phytochemicals identified from medicinal plant extracts against tuberculosis. doi:10.1080/07391102.2023.2213341 J Biomol Struct Dyn 2024
Phenotypic drug-susceptibility profiles and genetic analysis based on whole-genome sequencing of Mycobacterium avium complex isolates in Thailand. doi:10.1371/journal.pone.0294677 PLoS One 2023
Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China. doi:10.1016/j.heliyon.2023.e21216 Heliyon 2023
Whole genome sequencing-based identification of human tuberculosis caused by animal-lineage Mycobacterium orygis. doi:10.1128/jcm.00260-23 J Clin Microbiol 2023
GYRB - POLYMERASE CHAIN REACTION AND HISTOPATHOLOGIC CHARACTERISTIC FIGURE POTENTIAL FOR DETERMINING DIAGNOSIS OF TUBERCULOUS LYMPHADENITIS. doi:10.21010/Ajidv17i2S.3 names it Afr J Infect Dis 2023
Re-evaluation of critical concentrations of antituberculosis fluoroquinolones in the Mycobacteria Growth Indicator Tube 960 system. doi:10.4103/ijmy.ijmy_144_23 Int J Mycobacteriol 2023
Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan. doi:10.1016/j.jmii.2023.08.013 J Microbiol Immunol Infect 2023
Correlating clinical breakpoint concentration of moxifloxacin with gyrA mutations using the GenoType MTBDRsl assay Version 2.0. doi:10.1016/j.ijtb.2022.11.004 Indian J Tuberc 2023
Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage. doi:10.1016/j.jiph.2023.07.016 J Infect Public Health 2023
Characterization of Genetic Mutations in Multi-Drug-Resistant Isolates of Mycobacterium tuberculosis Bacilli Conferring Resistance to a Second-Line Anti-tuberculosis Drug. doi:10.7759/cureus.40442 Cureus 2023
Hi-plex deep amplicon sequencing for identification, high-resolution genotyping and multidrug resistance prediction of Mycobacterium leprae directly from patient biopsies by using Deeplex Myc-Lep. doi:10.1016/j.ebiom.2023.104649 EBioMedicine 2023
Comparison of the Diagnostic Performance of MeltPro and Next-Generation Sequencing in Determining Fluoroquinolone Resistance in Multidrug-Resistant Tuberculosis Isolates. doi:10.1016/j.jmoldx.2023.02.003 J Mol Diagn 2023
Distinct subunit architecture and assembly pattern of DNA gyrase from mycobacteria. doi:10.1111/mmi.15068 Mol Microbiol 2023
Strain diversity in Mycobacterium avium subsp. paratuberculosis-positive bovine fecal samples collected in Switzerland. doi:10.3389/fvets.2023.1154516 Front Vet Sci 2023
Isoflavonoid and Furanochromone Natural Products as Potential DNA Gyrase Inhibitors: Computational, Spectral, and Antimycobacterial Studies. doi:10.1021/acsomega.3c00684 ACS Omega 2023
Bioisosteric Design Identifies Inhibitors of Mycobacterium tuberculosis DNA Gyrase ATPase Activity. doi:10.1021/acs.jcim.2c01376 J Chem Inf Model 2023
Characterization of DNA Gyrase Activity and Elucidation of the Impact of Amino Acid Substitution in GyrA on Fluoroquinolone Resistance in Mycobacterium avium. doi:10.1128/spectrum.05088-22 Microbiol Spectr 2023
Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort. doi:10.1128/jcm.01478-22 J Clin Microbiol 2023
GenoType MTBDRsl for detection of second-line drugs and ethambutol resistance in multidrug-resistant Mycobacterium tuberculosis isolates at a high-throughput laboratory. doi:10.1016/j.diagmicrobio.2022.115856 Diagn Microbiol Infect Dis 2023
Drug resistance profiles and related gene mutations in slow-growing non-tuberculous mycobacteria isolated in regional tuberculosis reference laboratories of Iran: a three year cross-sectional study. doi:10.1080/20477724.2022.2049029 Pathog Glob Health 2023
Comparative genome analysis reveals high-level drug resistance markers in a clinical isolate of Mycobacterium fortuitum subsp. fortuitum MF GZ001. doi:10.3389/fcimb.2022.1056007 Front Cell Infect Microbiol 2022
An In-Silico Evaluation of Anthraquinones as Potential Inhibitors of DNA Gyrase B of Mycobacterium tuberculosis. doi:10.3390/microorganisms10122434 Microorganisms 2022
Genomic analysis of Mycobacterium tuberculosis variant bovis strains isolated from bovine in the state of Mato Grosso, Brazil. doi:10.3389/fvets.2022.1006090 Front Vet Sci 2022
High diversity of clinical Mycobacterium intracellulare in China revealed by whole genome sequencing. doi:10.3389/fpubh.2022.989587 Front Public Health 2022
Detection of Mutations in pncA in Mycobacterium tuberculosis Clinical Isolates from Nepal in Association with Pyrazinamide Resistance. doi:10.3390/cimb44090283 Curr Issues Mol Biol 2022
Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium simiae isolates obtained from regional tuberculosis reference laboratories of Iran. doi:10.1371/journal.pone.0267320 PLoS One 2022
Evaluation of the diagnostic value of loop-mediated isothermal amplification assays targeting three different Mycobacterium tuberculosis genes. doi:10.1016/j.mimet.2022.106547 J Microbiol Methods 2022
Molecular Surveillance of Antimicrobial Resistance of Mycobacterium leprae from Leprosy Patients in Zhejiang Province, China. doi:10.2147/IDR.S368682 Infect Drug Resist 2022
Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. doi:10.1016/S2666-5247(22)00117-3 Lancet Microbe 2022
[Exploratory study on detection of drug resistance of Mycobacterium tuberculosis in sputum specimens by next-generation sequencing]. doi:10.3760/cma.j.cn112147-20211104-00775 Zhonghua Jie He He Hu Xi Za Zhi 2022
Potential therapeutic targets from Mycobacterium abscessus (Mab): recently reported efforts towards the discovery of novel antibacterial agents to treat Mab infections. doi:10.1039/d1md00359c RSC Med Chem 2022
Characterization of Fluoroquinolone-Resistant and Multidrug-Resistant Mycobacterium tuberculosis Isolates Using Whole-Genome Sequencing in Tianjin, China. doi:10.2147/IDR.S361635 Infect Drug Resist 2022
Molecular Epidemiology and Polymorphism Analysis in Drug-Resistant Genes in M. tuberculosis Clinical Isolates from Western and Northern India. doi:10.2147/IDR.S345855 Infect Drug Resist 2022
Molecular characterisation of second-line drug resistance among drug resistant tuberculosis patients tested in Uganda: a two and a half-year's review. doi:10.1186/s12879-022-07339-w BMC Infect Dis 2022
Use of a gyrB PCR-RFLP method to diagnose tuberculosis and identify the causative Mycobacterium sp. in cattle and humans. doi:10.1016/j.cimid.2022.101767 names it Comp Immunol Microbiol Infect Dis 2022
Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China. doi:10.1128/spectrum.01475-21 Microbiol Spectr 2022
In Vitro Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. doi:10.1128/spectrum.01321-21 Microbiol Spectr 2022
Molecular Characteristic of Both Levofloxacin and Moxifloxacin Resistance in Mycobacterium tuberculosis from Individuals Diagnosed with Preextensive Drug-Resistant Tuberculosis. doi:10.1089/mdr.2021.0212 Microb Drug Resist 2022
Intradermal comparative cervical tuberculin test in the diagnosis of caprine tuberculosis. doi:10.1007/s42770-021-00650-9 Braz J Microbiol 2022
Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013. doi:10.1128/Spectrum.00409-21 Microbiol Spectr 2021
Correlation of gyr Mutations with the Minimum Inhibitory Concentrations of Fluoroquinolones among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Bangladesh. doi:10.3390/pathogens10111422 Pathogens 2021
The pipeline of new molecules and regimens against drug-resistant tuberculosis. doi:10.1016/j.jctube.2021.100285 J Clin Tuberc Other Mycobact Dis 2021
Mycobacterium microti Infection in Wild Boar (Sus scrofa): Histopathology Analysis Suggests Containment of the Infection. doi:10.3389/fvets.2021.734919 Front Vet Sci 2021
Characterizing the gene mutations associated with resistance to gatifloxacin in Mycobacterium tuberculosis through whole-genome sequencing. doi:10.1016/j.ijid.2021.09.028 Int J Infect Dis 2021
First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections. doi:10.1128/AAC.01208-21 names it Antimicrob Agents Chemother 2021
Simultaneous Determination of Mycobacterium leprae Drug Resistance and Single-Nucleotide Polymorphism Genotype by Use of Nested Multiplex PCR with Amplicon Sequencing. doi:10.1128/JCM.00814-21 J Clin Microbiol 2021
Quantification of pathogens and antibiotic resistance genes in backyard and commercial composts. doi:10.1016/j.scitotenv.2021.149197 Sci Total Environ 2021
A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance. doi:10.1016/j.cmi.2021.07.007 Clin Microbiol Infect 2021
Highly specific and sensitive detection of the Mycobacterium tuberculosis complex using multiplex loop-mediated isothermal amplification combined with a nanoparticle-based lateral flow biosensor. doi:10.1007/s42770-021-00520-4 Braz J Microbiol 2021
Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance. doi:10.1016/j.ijantimicag.2021.106385 Int J Antimicrob Agents 2021
Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan. doi:10.1038/s41598-021-91757-4 Sci Rep 2021
Interaction of Quinolones Carrying New R1 Group with Mycobacterium leprae DNA Gyrase. doi:10.1089/mdr.2020.0408 Microb Drug Resist 2021
Computational modeling and bioinformatic analyses of functional mutations in drug target genes in Mycobacterium tuberculosis. doi:10.1016/j.csbj.2021.04.034 Comput Struct Biotechnol J 2021
Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus. doi:10.1128/AAC.00676-21 Antimicrob Agents Chemother 2021
Loop-mediated isothermal amplification (LAMP) assay targeting RLEP for detection of Mycobacterium leprae in leprosy patients. doi:10.1016/j.ijid.2021.04.041 Int J Infect Dis 2021
Increasing prevalence of resistance to second-line drugs among multidrug-resistant Mycobacterium tuberculosis isolates in Kuwait. doi:10.1038/s41598-021-87516-0 Sci Rep 2021
Molecular Characteristics and Drug Resistance of Mycobacterium tuberculosis Isolate Circulating in Shaanxi Province, Northwestern China. doi:10.1089/mdr.2020.0496 Microb Drug Resist 2021
Molecular characterization of mutations associated with resistance to second line drugs in Mycobacterium tuberculosis patients from Casablanca, Morocco. doi:10.1590/S1678-9946202163019 Rev Inst Med Trop Sao Paulo 2021
Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey. doi:10.1016/j.jinf.2021.02.004 J Infect 2021
Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China. doi:10.1371/journal.pntd.0009068 PLoS Negl Trop Dis 2021
Genotyping and Molecular Characterization of Fluoroquinolone's Resistance Among Multidrug-Resistant Mycobacterium tuberculosis in Southwest of China. doi:10.1089/mdr.2019.0339 Microb Drug Resist 2021
Emergence of Specific gyrA Mutations Associated High-Level Fluoroquinolone-Resistant Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Cases in North India. doi:10.1089/mdr.2020.0240 Microb Drug Resist 2021
Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance. doi:10.1093/cid/ciaa496 Clin Infect Dis 2021
Isolation, Molecular Typing, and Antibiotic Susceptibility Testing of Mycobacterium avium Subspecies hominissuis From a Dog With Generalized Mycobacteriosis. doi:10.3389/fvets.2020.569966 Front Vet Sci 2020
Structure-Based Screening of DNA GyraseB Inhibitors for Therapeutic Applications in Tuberculosis: a Pharmacoinformatics Study. doi:10.1007/s12010-020-03374-y Appl Biochem Biotechnol 2020
Survey of drug resistance associated gene mutations in Mycobacterium tuberculosis, ESKAPE and other bacterial species. doi:10.1038/s41598-020-65766-8 Sci Rep 2020
Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran. doi:10.1186/s12879-020-05112-5 BMC Infect Dis 2020
Genotype analysis of ofloxacin-resistant multidrug-resistant Mycobacterium tuberculosis isolates in a multicentered study from India. doi:10.4103/ijmr.IJMR_493_18 Indian J Med Res 2020
Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil. doi:10.1590/0074-02760200055 Mem Inst Oswaldo Cruz 2020
Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients. doi:10.1186/s12890-020-1172-4 BMC Pulm Med 2020
Detection of drug resistant Mycobacterium tuberculosis by high-throughput sequencing of DNA isolated from acid fast bacilli smears. doi:10.1371/journal.pone.0232343 PLoS One 2020
Artificial Intelligence and Machine learning based prediction of resistant and susceptible mutations in Mycobacterium tuberculosis. doi:10.1038/s41598-020-62368-2 Sci Rep 2020
Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria. doi:10.1021/acsinfecdis.0c00025 names it ACS Infect Dis 2020
Burden of baseline resistance of Mycobacterium tuberculosis to fluoroquinolones and second-line injectables in central India. doi:10.1093/trstmh/trz121 Trans R Soc Trop Med Hyg 2020
Epidemiological cut-offs for Sensititre susceptibility testing of Mycobacterium tuberculosis: interpretive criteria cross validated with whole genome sequencing. doi:10.1038/s41598-020-57992-x Sci Rep 2020
Functional interactions between gyrase subunits are optimized in a species-specific manner. doi:10.1074/jbc.RA119.010245 J Biol Chem 2020
Diagnostic accuracy of droplet digital PCR analysis of cerebrospinal fluid for tuberculous meningitis in adult patients. doi:10.1016/j.cmi.2019.07.015 Clin Microbiol Infect 2020
Evaluation of MTBDRsl for detecting resistance in Mycobacterium tuberculosis to second-line drugs. doi:10.5588/ijtld.18.0562 Int J Tuberc Lung Dis 2019
Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China. doi:10.21037/jtd.2019.11.03 J Thorac Dis 2019
Anti-Tubercular Activity of Substituted 7-Methyl and 7-Formylindolizines and In Silico Study for Prospective Molecular Target Identification. doi:10.3390/antibiotics8040247 Antibiotics (Basel) 2019
Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan. doi:10.1038/s41598-019-51562-6 Sci Rep 2019
Molecular surveillance of antimicrobial resistance and transmission pattern of Mycobacterium leprae in Chinese leprosy patients. doi:10.1080/22221751.2019.1677177 Emerg Microbes Infect 2019
In silico study directed towards identification of the key structural features of GyrB inhibitors targeting MTB DNA gyrase: HQSAR, CoMSIA and molecular dynamics simulations. doi:10.1080/1062936X.2019.1658218 names it SAR QSAR Environ Res 2019
A multilocus sequence typing scheme for Mycobacterium abscessus complex (MAB-multilocus sequence typing) using whole-genome sequencing data. doi:10.4103/ijmy.ijmy_106_19 Int J Mycobacteriol 2019
Prevalence, risk and genetic characteristics of drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China. doi:10.2147/IDR.S209971 Infect Drug Resist 2019
Three-reaction high-resolution melting assay for rapid differentiation of Mycobacterium tuberculosis complex members. doi:10.1002/mbo3.919 Microbiologyopen 2019
Mutation and Transmission Profiles of Second-Line Drug Resistance in Clinical Isolates of Drug-Resistant Mycobacterium tuberculosis From Hebei Province, China. doi:10.3389/fmicb.2019.01838 Front Microbiol 2019
DNA gyrase could be a crucial regulatory factor for growth and survival of Mycobacterium leprae. doi:10.1038/s41598-019-47364-5 Sci Rep 2019
Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016). doi:10.1186/s12890-019-0891-x BMC Pulm Med 2019
Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan. doi:10.1016/j.jiac.2019.05.028 J Infect Chemother 2019
Characterisation of drug resistance-associated mutations among clinical multidrug-resistant Mycobacterium tuberculosis isolates from Hebei Province, China. doi:10.1016/j.jgar.2019.03.012 J Glob Antimicrob Resist 2019
Prevalence and detection of drug resistant mutations in Mycobacterium tuberculosis among drug naïve patients in Nairobi, Kenya. doi:10.1186/s12879-019-3911-9 BMC Infect Dis 2019
Development of a new High Resolution Melting (HRM) assay for identification and differentiation of Mycobacterium tuberculosis complex samples. doi:10.1038/s41598-018-38243-6 Sci Rep 2019
Overall Structures of Mycobacterium tuberculosis DNA Gyrase Reveal the Role of a Corynebacteriales GyrB-Specific Insert in ATPase Activity. doi:10.1016/j.str.2019.01.004 names it Structure 2019
Mutational analysis of gyrB at amino acids: G481A & D505A in multidrug resistant (MDR) tuberculosis patients. doi:10.1016/j.jiph.2019.01.056 names it J Infect Public Health 2019
Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis. doi:10.1002/jcb.27579 J Cell Biochem 2019
Design of novel quinoline-aminopiperidine derivatives as Mycobacterium tuberculosis (MTB) GyrB inhibitors: an in silico study. doi:10.1080/07391102.2018.1498806 names it J Biomol Struct Dyn 2019
rpoB Targeted Loop-Mediated Isothermal Amplification (LAMP) Assay for Consensus Detection of Mycobacteria Associated With Pulmonary Infections. doi:10.3389/fmed.2018.00332 Front Med (Lausanne) 2018
Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis. doi:10.1016/j.tube.2018.09.001 names it Tuberculosis (Edinb) 2018
Rewired Downregulation of DNA Gyrase Impacts Cell Division, Expression of Topology Modulators, and Transcription in Mycobacterium smegmatis. doi:10.1016/j.jmb.2018.10.001 J Mol Biol 2018
Description of a novel species of fast growing mycobacterium: Mycobacterium kyogaense sp. nov., a scotochromogenic strain received as Mycobacterium vaccae. doi:10.1099/ijsem.0.003039 Int J Syst Evol Microbiol 2018
In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis. doi:10.1016/j.tube.2018.08.005 Tuberculosis (Edinb) 2018
Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates. doi:10.1128/AAC.00527-18 names it Antimicrob Agents Chemother 2018
Recent progress in the discovery and development of DNA gyrase B inhibitors. doi:10.4155/fmc-2017-0257 Future Med Chem 2018
Regulation of the gyr operon of Mycobacterium tuberculosis by overlapping promoters, DNA topology, and reiterative transcription. doi:10.1016/j.bbrc.2018.05.067 Biochem Biophys Res Commun 2018
Single-nucleotide polymorphisms related to fluoroquinolone and aminoglycoside resistance in Mycobacterium avium isolates. doi:10.2147/IDR.S160899 Infect Drug Resist 2018
Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. doi:10.1016/S1473-3099(18)30073-2 Lancet Infect Dis 2018
Diagnostic accuracy of GenoType(®) MTBDRsl VER 2.0 in detecting second-line drug resistance to M. tuberculosis. doi:10.5588/ijtld.17.0663 Int J Tuberc Lung Dis 2018
Performance of Sequencing in Predicting Ofloxacin Resistance in Mycobacterium tuberculosis from Positive Bactec MGIT 960 Cultures. Ann Clin Lab Sci 2018
Second-line anti-tuberculosis drug resistance testing in Ghana identifies the first extensively drug-resistant tuberculosis case. doi:10.2147/IDR.S152720 Infect Drug Resist 2018
Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco. doi:10.1186/s12879-018-3009-9 BMC Infect Dis 2018
Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii. doi:10.1128/AAC.01788-17 Antimicrob Agents Chemother 2018
Genotypic detection of fluoroquinolone resistance in drug-resistant Mycobacterium tuberculosis at a tertiary care centre in south Coastal Karnataka, India. doi:10.1016/j.jgar.2018.01.023 J Glob Antimicrob Resist 2018
In Vitro Activity and MIC of Sitafloxacin against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis Isolated in Thailand. doi:10.1128/AAC.00825-17 Antimicrob Agents Chemother 2018
Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco. doi:10.1016/j.jgar.2017.10.003 names it J Glob Antimicrob Resist 2018
Molecular characteristics of ofloxacin mono-resistant Mycobacterium tuberculosis isolates from new and previously treated tuberculosis patients. doi:10.1002/jcla.22202 J Clin Lab Anal 2018
Mutation analysis for detection of drug resistance in mycobacterium tuberculosis isolates from Khyber Pakhtunkhwa, Pakistan. J Pak Med Assoc 2017
Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. doi:10.1093/cid/cix556 Clin Infect Dis 2017
Mycobacterium orygis Lymphadenitis in New York, USA. doi:10.3201/eid2310.170490 Emerg Infect Dis 2017
Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. doi:10.1056/NEJMoa1614915 N Engl J Med 2017
Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates. doi:10.3389/fmicb.2017.01539 Front Microbiol 2017
In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis. doi:10.4269/ajtmh.16-0478 Am J Trop Med Hyg 2017
High incidence of fluoroquinolone resistance and effect of efflux pump inhibitors on moxifloxacin resistance among Mycobacterium tuberculosis isolates causing urinary tract infection in Taiwan. doi:10.1016/j.ijantimicag.2017.04.010 Int J Antimicrob Agents 2017
Impact of gyrB and eis Mutations in Improving Detection of Second-Line-Drug Resistance among Mycobacterium tuberculosis Isolates from Georgia. doi:10.1128/AAC.01921-16 names it Antimicrob Agents Chemother 2017
In vitro activity of sitafloxacin against Mycobacterium tuberculosis with gyrA/B mutations isolated in Japan. doi:10.1099/jmm.0.000493 J Med Microbiol 2017
Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis? doi:10.1093/jac/dkx150 J Antimicrob Chemother 2017
Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis. doi:10.1093/jac/dkx110 J Antimicrob Chemother 2017
Double Mutants in DNA Gyrase Lead to Ofloxacin Resistance in Mycobacterium tuberculosis. doi:10.1002/jcb.25954 J Cell Biochem 2017
Identification of promising DNA GyrB inhibitors for Tuberculosis using pharmacophore-based virtual screening, molecular docking and molecular dynamics studies. doi:10.1111/cbdd.12949 names it Chem Biol Drug Des 2017
FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance. doi:10.1128/JCM.01662-16 J Clin Microbiol 2017
Evaluation of the GenoType MTBDRsl Version 2.0 Assay for Second-Line Drug Resistance Detection of Mycobacterium tuberculosis Isolates in South Africa. doi:10.1128/JCM.01865-16 J Clin Microbiol 2017
Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use. doi:10.1128/JCM.01771-16 J Clin Microbiol 2017
Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from high prevalence tuberculosis states in Mexico. doi:10.1016/j.meegid.2016.09.012 Infect Genet Evol 2017
Pre-Multidrug-Resistant Mycobacterium tuberculosis Infection Causing Fatal Enteric Disease in a Dog from a Family with History of Human Tuberculosis. doi:10.1111/tbed.12513 Transbound Emerg Dis 2017
Alternate efflux pump mechanism may contribute to drug resistance in extensively drug-resistant isolates of Mycobacterium tuberculosis. doi:10.1016/j.ijmyco.2016.09.064 Int J Mycobacteriol 2016
A Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, Russia. doi:10.1371/journal.pone.0167093 PLoS One 2016
Performance of the GenoType MTBDRplus assay (v2.0) and a new extended GenoType MTBDRsl assay (v2.0) for the molecular detection of multi- and extensively drug-resistant Mycobacterium tuberculosis on isolates primarily from Lithuania. doi:10.1016/j.diagmicrobio.2016.08.026 Diagn Microbiol Infect Dis 2016
Leprosy Drug Resistance Surveillance in Colombia: The Experience of a Sentinel Country. doi:10.1371/journal.pntd.0005041 PLoS Negl Trop Dis 2016
Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis. doi:10.1128/AAC.00664-16 Antimicrob Agents Chemother 2016
Mycobacterium Tuberculosis (MTB) GyrB inhibitors: An attractive approach for developing novel drugs against TB. doi:10.1016/j.ejmech.2016.08.034 names it Eur J Med Chem 2016
Digital PCR assay detection of circulating Mycobacterium tuberculosis DNA in pulmonary tuberculosis patient plasma. doi:10.1016/j.tube.2016.04.004 Tuberculosis (Edinb) 2016
The Chromosomal parDE2 Toxin-Antitoxin System of Mycobacterium tuberculosis H37Rv: Genetic and Functional Characterization. doi:10.3389/fmicb.2016.00886 Front Microbiol 2016
Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India. doi:10.1128/JCM.00670-16 names it J Clin Microbiol 2016
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin. doi:10.1128/AAC.00393-16 Antimicrob Agents Chemother 2016
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates. doi:10.1128/AAC.00539-16 names it Antimicrob Agents Chemother 2016
Quantification of colony-forming units for M. tuberculosis complex using gyrB-based real-time PCR assay. doi:10.5588/ijtld.15.0473 names it Int J Tuberc Lung Dis 2016
Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains. doi:10.1128/JCM.00051-16 J Clin Microbiol 2016
Simultaneous drug resistance detection and genotyping of Mycobacterium tuberculosis using a low-density hydrogel microarray. doi:10.1093/jac/dkw015 J Antimicrob Chemother 2016
Mycobacterium sherrisii visceral disseminated infection in an African HIV-infected adolescent. doi:10.1016/j.ijid.2016.02.011 Int J Infect Dis 2016
Structure-Guided Discovery of Antitubercular Agents That Target the Gyrase ATPase Domain. doi:10.1002/cmdc.201500556 ChemMedChem 2016
Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates. doi:10.1128/AAC.01049-15 names it Antimicrob Agents Chemother 2016
Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. doi:10.1128/JCM.02775-15 J Clin Microbiol 2016
Molecular characterization and drug susceptibility profile of a Mycobacterium avium subspecies avium isolate from a dog with disseminated infection. doi:10.1099/jmm.0.000221 J Med Microbiol 2016
Subspecies distribution and macrolide and fluoroquinolone resistance genetics of Mycobacterium abscessus in Korea. doi:10.5588/ijtld.15.0068 Int J Tuberc Lung Dis 2016
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors. doi:10.1016/j.bmc.2015.11.039 Bioorg Med Chem 2016
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. doi:10.1093/jac/dkv360 J Antimicrob Chemother 2016
Prevalence of mutations conferring resistance among multi- and extensively drug-resistant Mycobacterium tuberculosis isolates in China. doi:10.1038/ja.2015.106 J Antibiot (Tokyo) 2016
Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates. doi:10.1016/j.jmii.2015.04.003 J Microbiol Immunol Infect 2016
Spatiotemporal and Ecological Patterns of Mycobacterium microti Infection in Wild Boar (Sus scrofa). doi:10.1111/tbed.12313 Transbound Emerg Dis 2016
[Detection of mutations in the gyrA and gyrB genes associated with fluoroquinolone-resistance among clinical isolates of Mycobacterium abscessus in China]. names it Zhonghua Jie He He Hu Xi Za Zhi 2015
Molecular characterization of Mycobacterium orygis isolates from wild animals of Nepal. Jpn J Vet Res 2015
4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation. doi:10.1016/j.ejmech.2015.06.032 names it Eur J Med Chem 2015
Proteomic analysis of ofloxacin-mono resistant Mycobacterium tuberculosis isolates. doi:10.1016/j.jprot.2015.07.031 J Proteomics 2015
Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. doi:10.1371/journal.pone.0120470 names it PLoS One 2015
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors. doi:10.1016/j.bmc.2015.03.004 Bioorg Med Chem 2015
Development of 2-amino-5-phenylthiophene-3-carboxamide derivatives as novel inhibitors of Mycobacterium tuberculosis DNA GyrB domain. doi:10.1016/j.bmc.2015.02.032 names it Bioorg Med Chem 2015
Whole genome sequencing based characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from Pakistan. doi:10.1371/journal.pone.0117771 PLoS One 2015
Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes. doi:10.1128/mBio.02273-14 mBio 2015
Low resistance to first and second line anti-tuberculosis drugs among treatment naive pulmonary tuberculosis patients in southwestern Uganda. doi:10.1371/journal.pone.0118191 PLoS One 2015
Evaluation of a low-density hydrogel microarray technique for mycobacterial species identification. doi:10.1128/JCM.02579-14 J Clin Microbiol 2015
Novel amide and sulphonamide derivatives of 6-(piperazin-1-yl)phenanthridine as potent Mycobacterium tuberculosis H37Rv inhibitors. doi:10.1016/j.ejmech.2015.01.013 Eur J Med Chem 2015
Enabling the (3 + 2) cycloaddition reaction in assembling newer anti-tubercular lead acting through the inhibition of the gyrase ATPase domain: lead optimization and structure activity profiling. doi:10.1039/c4ob02049a Org Biomol Chem 2015
Detailed investigation of the microbial community in foaming activated sludge reveals novel foam formers. doi:10.1038/srep07637 Sci Rep 2015
Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: hit to lead optimization of a novel class of thiazole inhibitors. doi:10.1016/j.bmc.2014.12.001 Bioorg Med Chem 2015
Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis. doi:10.1128/AAC.04058-14 Antimicrob Agents Chemother 2015
Molecular characterisation of extensively drug-resistant Mycobacterium tuberculosis isolates in China. doi:10.1016/j.ijantimicag.2014.09.018 Int J Antimicrob Agents 2015
Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase. doi:10.1177/1087057114554170 J Biomol Screen 2015
Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin. doi:10.1038/ja.2014.95 J Antibiot (Tokyo) 2015
The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis. doi:10.1128/microbiolspec.MGM2-0009-2013 Microbiol Spectr 2014
[Analysis of genetic determinants of multidrug and extensively drug-resistant Mycobacterium tuberculosis using oligonucleotide microchip]. Mol Biol (Mosk) 2014
An efficient synthesis and biological screening of benzofuran and benzo[d]isothiazole derivatives for Mycobacterium tuberculosis DNA GyrB inhibition. doi:10.1016/j.bmc.2014.10.016 names it Bioorg Med Chem 2014
Mycobacterial DNA gyrB inhibitors: Ligand based pharmacophore modelling and in vitro enzyme inhibition studies. doi:10.2174/1568026613666140929123833 names it Curr Top Med Chem 2014
Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis. doi:10.2147/IDR.S65417 Infect Drug Resist 2014
Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia. doi:10.1186/1471-2334-14-478 BMC Infect Dis 2014
Discovery of Novel Mycobacterial DNA Gyrase B Inhibitors: In Silico and In Vitro Biological Evaluation. doi:10.1002/minf.201400058 Mol Inform 2014
[Heteroresistance in Mycobacteria tuberculosis is an important factor for the inconsistency between the results of phenotype and genotype drug susceptibility tests]. Zhonghua Jie He He Hu Xi Za Zhi 2014
Gyrase ATPase domain as an antitubercular drug discovery platform: structure-based design and lead optimization of nitrothiazolyl carboxamide analogues. doi:10.1002/cmdc.201402035 ChemMedChem 2014
Amycolatopsis roodepoortensis sp. nov. and Amycolatopsis speibonae sp. nov.: antibiotic-producing actinobacteria isolated from South African soils. doi:10.1038/ja.2014.79 J Antibiot (Tokyo) 2014
Detection and molecular characterization of Mycobacterium microti isolates in wild boar from northern Italy. doi:10.1128/JCM.00440-14 J Clin Microbiol 2014
Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China. doi:10.1128/AAC.02426-14 Antimicrob Agents Chemother 2014
MUBII-TB-DB: a database of mutations associated with antibiotic resistance in Mycobacterium tuberculosis. doi:10.1186/1471-2105-15-107 BMC Bioinformatics 2014
High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. doi:10.1128/AAC.02066-13 names it Antimicrob Agents Chemother 2014
Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. doi:10.1038/emi.2014.21 Emerg Microbes Infect 2014
Isolation of Mycobacterium caprae (Lechtal genotype) from red deer (Cervus elaphus) in Italy. doi:10.7589/2013-06-135 J Wildl Dis 2014
Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding. doi:10.1074/jbc.M113.529164 J Biol Chem 2014
Development of novel N-linked aminopiperidine-based mycobacterial DNA gyrase B inhibitors: scaffold hopping from known antibacterial leads. doi:10.1016/j.ijantimicag.2013.12.006 Int J Antimicrob Agents 2014
Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from China. doi:10.1128/AAC.01792-13 Antimicrob Agents Chemother 2014
Thiazolopyridone ureas as DNA gyrase B inhibitors: optimization of antitubercular activity and efficacy. doi:10.1016/j.bmcl.2013.12.080 Bioorg Med Chem Lett 2014
Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. doi:10.1128/JCM.02701-13 J Clin Microbiol 2014
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. doi:10.1128/AAC.01228-13 Antimicrob Agents Chemother 2014
Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis. doi:10.1128/AAC.01751-13 names it Antimicrob Agents Chemother 2014
Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. doi:10.1093/jac/dkt358 J Antimicrob Chemother 2014
Geographical differences associated with single-nucleotide polymorphisms (SNPs) in nine gene targets among resistant clinical isolates of Mycobacterium tuberculosis. doi:10.1128/JCM.00857-13 J Clin Microbiol 2014
Thiazole-aminopiperidine hybrid analogues: design and synthesis of novel Mycobacterium tuberculosis GyrB inhibitors. doi:10.1016/j.ejmech.2013.09.025 names it Eur J Med Chem 2013
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B. doi:10.1021/jm401268f J Med Chem 2013
Identification of the likely translational start of Mycobacterium tuberculosis GyrB. doi:10.1186/1756-0500-6-274 names it BMC Res Notes 2013
Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. doi:10.1128/AAC.00506-13 Antimicrob Agents Chemother 2013
Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system. doi:10.1093/jac/dkt202 J Antimicrob Chemother 2013
Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays. doi:10.1186/1471-2334-13-240 BMC Infect Dis 2013
Characterization of multiple and extensively drug resistant Mycobacterium tuberculosis isolates with different ofloxacin-resistance levels. doi:10.1016/j.tube.2013.02.005 Tuberculosis (Edinb) 2013
Region of difference 4 in alpine Mycobacterium caprae isolates indicates three variants. doi:10.1128/JCM.02966-12 J Clin Microbiol 2013
The naphthoquinone diospyrin is an inhibitor of DNA gyrase with a novel mechanism of action. doi:10.1074/jbc.M112.419069 J Biol Chem 2013
Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis. doi:10.1021/cb300510w names it ACS Chem Biol 2013
Bacterial classification of fish-pathogenic Mycobacterium species by multigene phylogenetic analyses and MALDI Biotyper identification system. doi:10.1007/s10126-012-9492-x Mar Biotechnol (NY) 2013
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. doi:10.1099/jmm.0.046821-0 names it J Med Microbiol 2013
Rapid tests for the detection of the Mycobacterium abscessus subsp. bolletii strain responsible for an epidemic of surgical-site infections in Brazil. doi:10.1590/s0074-02762012000800002 Mem Inst Oswaldo Cruz 2012
Impact of amino acid substitutions in B subunit of DNA gyrase in Mycobacterium leprae on fluoroquinolone resistance. doi:10.1371/journal.pntd.0001838 PLoS Negl Trop Dis 2012
Binding of two DNA molecules by type II topoisomerases for decatenation. doi:10.1093/nar/gks843 Nucleic Acids Res 2012
Popular molecular markers in bacteria. Mol Gen Mikrobiol Virusol 2012
Rapid and accurate identification of Mycobacterium tuberculosis complex and common non-tuberculous mycobacteria by multiplex real-time PCR targeting different housekeeping genes. doi:10.1007/s00284-012-0188-2 Curr Microbiol 2012
New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. doi:10.1371/journal.pone.0039754 names it PLoS One 2012
Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China. doi:10.1016/j.diagmicrobio.2012.03.025 Diagn Microbiol Infect Dis 2012
Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China. doi:10.1128/JCM.06860-11 J Clin Microbiol 2012
Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. doi:10.1016/s1413-8670(12)70294-5 names it Braz J Infect Dis 2012
Human Tuberculous Meningitis Caused by Mycobacterium caprae. doi:10.1159/000337299 Case Rep Neurol 2012
gyrA/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China. doi:10.1016/j.ijantimicag.2012.02.015 Int J Antimicrob Agents 2012
Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance. doi:10.1016/j.ijantimicag.2012.01.007 Int J Antimicrob Agents 2012
Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. doi:10.1128/AAC.05905-11 Antimicrob Agents Chemother 2012
Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. doi:10.1128/AAC.06272-11 names it Antimicrob Agents Chemother 2012
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. doi:10.1093/jac/dkr566 J Antimicrob Chemother 2012
Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs. doi:10.5588/ijtld.10.0600 Int J Tuberc Lung Dis 2012
The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. doi:10.5588/ijtld.11.0223 Int J Tuberc Lung Dis 2012
High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. doi:10.1128/JCM.05286-11 J Clin Microbiol 2012
Detection and discrimination of Mycobacterium tuberculosis complex. doi:10.1016/j.diagmicrobio.2011.09.021 Diagn Microbiol Infect Dis 2012
Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. doi:10.1093/jac/dkr449 J Antimicrob Chemother 2012
Phenotypic and molecular characterization of quinolone resistance in Mycobacterium abscessus subsp. bolletii recovered from postsurgical infections. doi:10.1099/jmm.0.034942-0 J Med Microbiol 2012
gyrA and gyrB gene mutation in ciprofloxacin-resistant Mycobacterium massiliense clinical isolates from Southern Brazil. doi:10.1089/mdr.2011.0047 names it Microb Drug Resist 2012
gyrA and gyrB mutations in ofloxacin-resistant Mycobacterium tuberculosis clinical isolates in Thailand. names it Southeast Asian J Trop Med Public Health 2011
Pyrosequencing assay for rapid identification of Mycobacterium tuberculosis complex species. doi:10.1186/1756-0500-4-423 BMC Res Notes 2011
Species distribution of the Mycobacterium tuberculosis complex in clinical isolates from 2007 to 2010 in Turkey: a prospective study. doi:10.1128/JCM.01172-11 J Clin Microbiol 2011
Characterization of mutations conferring extensive drug resistance to Mycobacterium tuberculosis isolates in Pakistan. doi:10.1128/AAC.05101-11 Antimicrob Agents Chemother 2011
Mycobacterial infection after intravesical bacillus Calmette-Guërin treatment for bladder cancer: a case report. doi:10.3343/kjlm.2011.31.3.197 Korean J Lab Med 2011
DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. doi:10.1128/AAC.00707-11 names it Antimicrob Agents Chemother 2011
The dimer state of GyrB is an active form: implications for the initial complex assembly and processive strand passage. doi:10.1093/nar/gkr553 names it Nucleic Acids Res 2011
Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas. doi:10.1128/JCM.00231-11 J Clin Microbiol 2011
Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. doi:10.1128/AAC.00042-11 names it Antimicrob Agents Chemother 2011
Evaluation of two molecular assays for rapid detection of mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance Settings. doi:10.1128/JCM.01889-10 J Clin Microbiol 2011
[Isolation and identification of a pyrene-degrading bacterial strain from contaminated soil]. Wei Sheng Wu Xue Bao 2011
Genotyping of Mycobacterium leprae from Brazilian leprosy patients suggests the occurrence of reinfection or of bacterial population shift during disease relapse. doi:10.1099/jmm.0.029389-0 J Med Microbiol 2011
Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. doi:10.1128/JCM.00197-11 J Clin Microbiol 2011
Population-based investigation of fluoroquinolones resistant tuberculosis in rural eastern China. doi:10.1016/j.tube.2011.03.001 Tuberculosis (Edinb) 2011
Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. doi:10.1186/1471-2334-11-78 BMC Infect Dis 2011
Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India. doi:10.1128/JCM.00113-11 J Clin Microbiol 2011
Multiplexed typing of Mycobacterium avium subsp. paratuberculosis types I, II, and III by Luminex xMAP suspension array. doi:10.1128/JCM.01761-10 J Clin Microbiol 2011
[The effects of gene mutation related to drug resistance and drug efflux pump in extensively drug-resistant tuberculosis clinical isolates]. Zhonghua Jie He He Hu Xi Za Zhi 2010
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. doi:10.1128/AAC.00968-10 Antimicrob Agents Chemother 2010
[Molecular characterization of drug-resistant and extensive-drug resistant isolates of Mycobacterium tuberculosis in Shenzhen of China]. Zhonghua Jie He He Hu Xi Za Zhi 2010
Identification of Mycobacterium tuberculosis clinical isolates in Bangladesh by a species distinguishable multiplex PCR. doi:10.1186/1471-2334-10-118 BMC Infect Dis 2010
Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. doi:10.1016/j.jinf.2010.05.001 names it J Infect 2010
Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. doi:10.1128/JCM.01947-09 J Clin Microbiol 2010
Differentiation of clinical Mycobacterium tuberculosis complex isolates by their GyrB polymorphism. doi:10.4103/0255-0857.58724 names it Indian J Med Microbiol 2010
Gold nanoprobe assay for the identification of mycobacteria of the Mycobacterium tuberculosis complex. doi:10.1111/j.1469-0691.2009.03120.x Clin Microbiol Infect 2010
First report of molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates from a Tunisian hospital. doi:10.1111/j.1469-0691.2009.03087.x Clin Microbiol Infect 2010
A novel and more sensitive loop-mediated isothermal amplification assay targeting IS6110 for detection of Mycobacterium tuberculosis complex. doi:10.1016/j.micres.2009.05.001 Microbiol Res 2010
[Species-specific detection of Mycobacterium tuberculosis complex]. Tuberk Biolezni Legkih 2009
Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. doi:10.1128/AAC.00541-09 Antimicrob Agents Chemother 2009
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. doi:10.1128/AAC.00287-09 names it Antimicrob Agents Chemother 2009
Unique genotypes of Mycobacterium avium subsp. paratuberculosis strains of Type III. doi:10.1016/j.vetmic.2009.06.011 Vet Microbiol 2009
Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. doi:10.1128/AAC.00050-09 Antimicrob Agents Chemother 2009
[Differentiation of species within the Mycobacterium tuberculosis complex by molecular techniques]. doi:10.1016/j.eimc.2009.01.008 Enferm Infecc Microbiol Clin 2009
Crystallization and preliminary crystallographic studies of Mycobacterium tuberculosis DNA gyrase B C-terminal domain, part of the enzyme reaction core. doi:10.1107/S1744309109006575 Acta Crystallogr Sect F Struct Biol Cryst Commun 2009
Molecular detection of drug-resistant Mycobacterium tuberculosis with a scanning-frame oligonucleotide microarray. doi:10.1007/978-1-59745-207-6_26 Methods Mol Biol 2009
Mycobacterium tuberculosis and nontuberculous mycobacterial isolates among patients with recent HIV infection in Mozambique. doi:10.1590/s1806-37132008001000011 J Bras Pneumol 2008
A single-step sequencing method for the identification of Mycobacterium tuberculosis complex species. doi:10.1371/journal.pntd.0000253 PLoS Negl Trop Dis 2008
Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. doi:10.1128/AAC.00036-08 Antimicrob Agents Chemother 2008
[Rd7 genotyping of M. tuberculosis strains isolated from patients with lung tuberculosis in different areas of Kazakhstan]. Mol Gen Mikrobiol Virusol 2008
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. doi:10.1128/AAC.01380-07 names it Antimicrob Agents Chemother 2008
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? doi:10.1128/AAC.01095-07 Antimicrob Agents Chemother 2008
Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. doi:10.2174/187152607781001763 Infect Disord Drug Targets 2007
Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. doi:10.1159/000109769 Chemotherapy 2007
Characterization of Mycobacterium africanum subtype I among cows in a dairy farm in Bangladesh using spoligotyping. Southeast Asian J Trop Med Public Health 2007
[Detection of Mycobacterium species distribution in the sputum samples of tuberculosis patients by PCR-RFLP method in Elazig province]. Mikrobiyol Bul 2007
Polymorphisms in gyrA and gyrB genes among Mycobacterium avium subsp. paratuberculosis type I, II, and III isolates. doi:10.1128/JCM.01411-07 names it J Clin Microbiol 2007
Refractory osteomyelitis caused by bacille Calmette-Guérin vaccination: a case report. doi:10.1016/j.diagmicrobio.2007.04.011 Diagn Microbiol Infect Dis 2007
Treatment failure in a case of extensively drug-resistant tuberculosis associated with selection of a GyrB mutant causing fluoroquinolone resistance. doi:10.1007/s10096-007-0298-0 names it Eur J Clin Microbiol Infect Dis 2007
Diversity of environmental Mycobacterium isolates from hemodialysis water as shown by a multigene sequencing approach. doi:10.1128/AEM.02934-06 Appl Environ Microbiol 2007
Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. doi:10.1093/jac/dkm061 J Antimicrob Chemother 2007
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. doi:10.1128/AAC.01282-06 Antimicrob Agents Chemother 2007
A microbial diagnostic microarray technique for the sensitive detection and identification of pathogenic bacteria in a background of nonpathogens. doi:10.1016/j.ab.2006.09.026 Anal Biochem 2007
Genomic diversity in Mycobacterium avium: single nucleotide polymorphisms between the S and C strains of M. avium subsp. paratuberculosis and with M. a. avium. doi:10.1016/j.mcp.2006.08.002 Mol Cell Probes 2007
Study of the gyrB gene polymorphism as a tool to differentiate among Mycobacterium tuberculosis complex subspecies further underlines the older evolutionary age of 'Mycobacterium canettii'. doi:10.1016/j.mcp.2005.11.008 names it Mol Cell Probes 2006
Comparative study of two typing methods, hsp65 PRA and ITS sequencing, revealed a possible evolutionary link between Mycobacterium kansasii type I and II isolates. doi:10.1111/j.1574-6968.2005.00013.x FEMS Microbiol Lett 2006
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. doi:10.1128/AAC.50.1.104-112.2006 Antimicrob Agents Chemother 2006
[Microbiological and molecular analysis of mycobacterium tuberculosis complex strains isolated from patients with pulmonary tuberculosis]. Pneumonol Alergol Pol 2005
Spoligotyping and pncA polymorphism: a two step scenario for Mycobacterium bovis diagnosis in Portugal. doi:10.1016/s0873-2159(15)30528-6 Rev Port Pneumol 2005
Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. names it Southeast Asian J Trop Med Public Health 2005
Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. doi:10.1093/jac/dki353 J Antimicrob Chemother 2005
A monoclonal antibody that inhibits mycobacterial DNA gyrase by a novel mechanism. doi:10.1093/nar/gki622 Nucleic Acids Res 2005
Mycobacterium tuberculosis complex differentiation using gyrB-restriction fragment length polymorphism analysis. doi:10.1590/s0074-02762004000700014 names it Mem Inst Oswaldo Cruz 2004
[Comparison of two reverse hybridization methods for mycobacterial identification in clinical practice]. doi:10.1016/j.patbio.2004.07.018 Pathol Biol (Paris) 2004
The species Mycobacterium africanum in the light of new molecular markers. doi:10.1128/JCM.42.9.3958-3962.2004 J Clin Microbiol 2004
[Molecular identification of mycobacteria and detection of antibiotic resistance]. Ann Biol Clin (Paris) 2004
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. doi:10.1128/AAC.48.4.1281-1288.2004 Antimicrob Agents Chemother 2004
Elevation of Mycobacterium tuberculosis subsp. caprae Aranaz et al. 1999 to species rank as Mycobacterium caprae comb. nov., sp. nov. doi:10.1099/ijs.0.02532-0 Int J Syst Evol Microbiol 2003
Mycobacterium bovis subsp. caprae caused one-third of human M. bovis-associated tuberculosis cases reported in Germany between 1999 and 2001. doi:10.1128/JCM.41.7.3070-3077.2003 J Clin Microbiol 2003
Loop-mediated isothermal amplification for direct detection of Mycobacterium tuberculosis complex, M. avium, and M. intracellulare in sputum samples. doi:10.1128/JCM.41.6.2616-2622.2003 J Clin Microbiol 2003
Detection and identification of Mycobacterium species isolates by DNA microarray. doi:10.1128/JCM.41.6.2605-2615.2003 J Clin Microbiol 2003
Detection of gene mutations related with drug resistance in Mycobacterium leprae from leprosy patients using Touch-Down (TD) PCR. doi:10.1016/S0928-8244(03)00038-5 FEMS Immunol Med Microbiol 2003
Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. doi:10.1128/JCM.41.3.1311-1315.2003 J Clin Microbiol 2003
An orphan gyrB in the Mycobacterium smegmatis genome uncovered by comparative genomics. doi:10.1007/BF02715907 names it J Genet 2002
DNA gyrase genes in Mycobacterium tuberculosis: a single operon driven by multiple promoters. doi:10.1128/JB.184.19.5449-5456.2002 J Bacteriol 2002
Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. doi:10.1016/s1201-9712(02)90136-0 Int J Infect Dis 2002
Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase. doi:10.1093/nar/30.10.2144 Nucleic Acids Res 2002
Biochemical and genetic evidence for the transfer of Mycobacterium tuberculosis subsp. caprae Aranaz et al. 1999 to the species Mycobacterium bovis Karlson and Lessel 1970 (approved lists 1980) as Mycobacterium bovis subsp. caprae comb. nov. doi:10.1099/00207713-52-2-433 Int J Syst Evol Microbiol 2002
Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. doi:10.1128/AAC.46.2.443-450.2002 Antimicrob Agents Chemother 2002
A Mycobacterium smegmatis gyrase B specific monoclonal antibody reveals association of gyrase A and B subunits in the cell. doi:10.1111/j.1574-6968.2001.tb09451.x FEMS Microbiol Lett 2001
Differentiation of clinical Mycobacterium tuberculosis complex isolates by gyrB DNA sequence polymorphism analysis. doi:10.1128/JCM.38.9.3231-3234.2000 names it J Clin Microbiol 2000
Differentiation of phylogenetically related slowly growing mycobacteria by their gyrB sequences. doi:10.1128/JCM.38.1.301-308.2000 names it J Clin Microbiol 2000
Regulation of DNA gyrase operon in Mycobacterium smegmatis: a distinct mechanism of relaxation stimulated transcription. doi:10.1046/j.1365-2443.1999.00296.x Genes Cells 1999
Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. doi:10.1128/AAC.42.8.2084 Antimicrob Agents Chemother 1998
Gene arrangement and organization in a approximately 76 kb fragment encompassing the oriC region of the chromosome of Mycobacterium leprae. doi:10.1099/13500872-142-11-3147 Microbiology (Reading) 1996
Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis. doi:10.1128/AAC.40.9.2054 Antimicrob Agents Chemother 1996
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. doi:10.1128/AAC.40.8.1768 Antimicrob Agents Chemother 1996
Organization of the origins of replication of the chromosomes of Mycobacterium smegmatis, Mycobacterium leprae and Mycobacterium tuberculosis and isolation of a functional origin from M. smegmatis. doi:10.1111/j.1365-2958.1996.tb02617.x Mol Microbiol 1996
Mycobacterium smegmatis DNA gyrase: cloning and overexpression in Escherichia coli. doi:10.1099/13500872-141-12-3029 Microbiology (Reading) 1995
Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. doi:10.2165/00003495-199500492-00006 Drugs 1995
Molecular cloning of gyrA and gyrB genes of Mycobacterium tuberculosis: analysis of nucleotide sequence. names it Biochem Mol Biol Int 1994
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. doi:10.1128/AAC.38.4.773 names it Antimicrob Agents Chemother 1994

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

Transcriptional start site (informative, coordinates unchanged)

Primary TSS at position 5181 (+ strand), 176 bp 5'UTR. TSS-derived candidate start codon: 5357 (108 bp from the annotated start) -- candidate only, not applied to this record's coordinates.

Genome-wide 5'-triphosphate-enriched RNA-seq TSS mapping (Cortes et al. 2013): informative context on transcript architecture only. reannotated_start_candidate is the authors' TSS-derived candidate start codon -- reported for information, NEVER applied to this atlas's start_mtbc0/end_mtbc0 coordinates (P19 MTBC0<->H37Rv anchoring). Row re-keyed to this locus by matching its genomic boundary against the H37Rv GFF3 (P49.1 (phase233, 2026-09-15), P49): the original ingestion (P16.23/phase135, 2026-08-17) trusted the source table's own gene-identity column, which was desynchronised from its own numeric columns on 547/651 checkable rows -- see P49 for the full diagnostic. A missing primary_tss here means this gene falls outside the 680-gene re-annotation-candidate subset the source table covers, not an absence of transcription. Source: Cortes et al. 2013 (Cell Reports), Table S3 (TSS mapping and re-annotation of start codons), 680-gene re-annotation-candidate subset of >4,000 genome-wide TSS -- row re-keyed to this locus by coordinate match (P49).

CRISPRi vulnerability

Vulnerability index -11.39 (95% CI -12.28 to -10.49). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Legacy record & comparison (Mycobrowser)

Mycobrowser functionDNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings [catalytic activity: ATP-dependent breakage, passage and rejoining of double-stranded DNA].
Mycobrowser EC 5.99.1.3 · agrees with the atlas

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb0005 · 99.9% identity
M. leprae ML0005 · 86.5% identity
M. marinum MMAR_0005 · 89.8% identity
M. smegmatis MSMEG_0005 · 85.9% identity
M. orygis RJtmp_000005 · 99.4% identity
M. abscessus MAB_0006 · 87.9% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt P9WG45 SwissProt · reviewed · Evidence at protein level
UniProt nameDNA gyrase subunit B
EC (curated) EC 5.6.2.2
Curated functionA type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to maintain chromosomes in an underwound state, while in the absence of ATP it relaxes supercoiled dsDNA. Also catalyzes the interconversion of other topological isomers of dsDNA rings, including catenanes. Gyrase from M.tuberculosis has higher decatenation than supercoiling activity compared to E.coli; as M.tuberculosis only has 1 type II topoisomerase, gyrase has to fulfill the decatenation function of topoisomerase IV as well. At comparable concentrations M.tuberculosis gyr.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category L Replication, recombination and repair
Preferred namegyrB
eggNOG descriptionA type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to modulate DNA topology and maintain chromosomes in an underwound state. Negative supercoiling favors strand separation, and DNA replication, transcription, recombination and repair, all of which involve strand separation. Also able to catalyze the interconversion of other topological isomers of dsDNA rings, including catenanes and knotted rings. Type II topoisomerases break and join 2 DNA strands simultaneously in an ATP-dependent manner
Orthologous groupCOG0187
EC number EC 5.99.1.3
KEGG orthology K02470
Gene Ontology (69) GO:0000166, GO:0000287, GO:0003674, GO:0003824, GO:0003916, GO:0003918, GO:0005488, GO:0005524, GO:0005575, GO:0005618, GO:0005623, GO:0005886 +57 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 0.552 · relaxed/neutral
Polymorphic sites (≥ 0.1% of strains) 8 synonymous, 14 missense, 0 nonsense, 0 frameshift

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Bacteria

M. canettii dN/dS (deep-divergence selection) 0.0 (low power) · 4 consensus substitution(s)
low power (4 canettii-consensus substitution(s)); present in M. canettii but dN/dS not reliable
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 53/53 (100%) · mean identity 91.4% · 4/4 closest MTBAP relatives
conserved across the genus (present in 53/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 13/13 non-Mycobacterium reference genomes (down to Bacteria) · mean identity 68.9%
detected down to outside the phylum (Proteobacteria/Firmicutes controls) — a universally conserved, ancient bacterial gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis) essential

DeJesus 2017 callES · essential
What the call meansessential: insertions absent across the whole ORF
TA sites (Himar1) 40 in the ORF — 39 in the essential state, 0 growth-defect, 1 non-essential, 0 growth-advantage. Saturation 0.025, mean read count 26. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 40 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Chemical-genetic target & druggability (PROSPECT) hypomorph tool strain

This gene is part of the PROSPECT collection of TetON transcriptional-knockdown (hypomorph) strains of essential M. tuberculosis genes, built as a sensitised background for chemical-genetic mechanism-of-action deconvolution. Being in the panel means the gene is an essential / vulnerable target for which a validated knockdown tool strain exists.

Hypomorph straingyrB-FLAG-tetOn-6 (TetON promoter 6)
Baseline knockdown fitness3.179 median doublings (across 6 screen pool(s)) — fewer doublings = stronger growth defect on knockdown
Used in target deconvolutionyes (informs phenotypic-cluster / MOA assignment)

Panel membership reflects essentiality/vulnerability and the availability of a genetic tool, not a specific molecular function; it never changes the verdict here. Source: Bond AN et al., Nat Commun 2025;16:9673 (doi:10.1038/s41467-025-64662-x); PROSPECT chemical-genetic platform.

Drug resistance (WHO catalogue) levofloxacinmoxifloxacin

levofloxacin15 catalogued resistance-associated variant(s)
moxifloxacin15 catalogued resistance-associated variant(s)

This gene carries mutations classed Associated with resistance (WHO grade 1–2) in the consolidated catalogue (WHO 2nd ed. 2023 + tb-profiler). Only the R-associated tier is shown; "uncertain" and empirical-only signals are excluded. Test a specific strain or variant with the resistance tester. Research context, not a clinical diagnostic.

Proteomics (mass spectrometry) detected

MS detectiondetected in 15 of 16 independent MS datasets
Integrated abundance432.0 ppm · rank 463/3519 (86.9th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) no export signal, no TM helix

Predictionno signal peptide, no TM helix (DeepTMHMM class GLOB)
DeepTMHMM classGLOB

A verified absence of signals, which is not a compartment. No Sec/Tat signal peptide, no transmembrane helix and no lipobox were found on this sequence. The predictor reports topology and export signals; it does not measure where the protein ends up, so this page draws no cytoplasmic conclusion from it. In M. tuberculosis that reservation is not theoretical: the 12 Esx paralogues of this atlas — EsxA/ESAT-6 and EsxB/CFP-10 among them, the best-established secreted proteins of the species — carry this very call, because substrates of the type VII (ESX) secretion system leave no recognisable signal. « Secreted » and « no signal peptide » are true together here.

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length675 aa
Molecular weight74.1 kDa
Theoretical pI5.98
GRAVY-0.362 (hydrophilic)
Aliphatic index85.5
Aromaticity0.065
Instability index28.3 (stable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
HATPase_cPF02518.32 3.2e-1539–176 Histidine kinase-, DNA gyrase B-, and HSP90-like ATPase
DNA_gyraseBPF00204.32 1.7e-63256–425 DNA gyrase B
ToprimPF01751.29 5.3e-17454–565 Toprim domain
DNA_gyraseB_CPF00986.27 3.1e-26606–663 DNA gyrase B subunit, carboxyl terminus

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 6gav (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 21 solved

PDBMethodResolutionCoverage
6gav X-ray diffraction 2.6 Å 100%
6gau X-ray diffraction 3.3 Å 100%
8s7o Electron Microscopy 2.8 Å 99%
8s7k Electron Microscopy 3.2 Å 99%
3zkb X-ray diffraction 2.9 Å 63%
3zkd X-ray diffraction 2.95 Å 63%
3zm7 X-ray diffraction 3.3 Å 63%
5bs8 X-ray diffraction 2.399 Å 37%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (21 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 89.0

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
6gav-assembly1_A 1.00 0.95 0.91 0.55 96% 96% / 55% 0.0e+00 sig 6gav-assembly1_A Extremely 'open' clamp structure of DNA gyrase: role of the Corynebacteriales GyrB specific insert
6gav-assembly1_B 1.00 0.94 0.91 0.55 95% 96% / 55% 0.0e+00 sig 6gav-assembly1_B Extremely 'open' clamp structure of DNA gyrase: role of the Corynebacteriales GyrB specific insert
6gau-assembly1_A 1.00 0.91 0.87 0.54 92% 96% / 55% 0.0e+00 sig 6gau-assembly1_A Extremely 'open' clamp structure of DNA gyrase: role of the Corynebacteriales GyrB specific insert
6gau-assembly1_B 1.00 0.90 0.84 0.54 91% 94% / 54% 1.0e-98 sig 6gau-assembly1_B Extremely 'open' clamp structure of DNA gyrase: role of the Corynebacteriales GyrB specific insert
3zkb-assembly1_D 1.00 0.95 0.56 0.95 94% 62% / 100% 1.7e-73 sig 3zkb-assembly1_D CRYSTAL STRUCTURE OF THE ATPASE REGION OF Mycobacterium tuberculosis GyrB WITH AMPPNP

Foldseek search of the AlphaFold DB model (mean pLDDT 89.0, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon) operon of 2

Upstream (5' on genome)Rv0004 (+ strand, 242 bp gap)
Downstream (3' on genome)gyrA (+ strand, 34 bp gap)
Predicted operon gyrB · gyrA

Neighbours from the H37Rv annotation (+ strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) operon of 3: gyrB · gyrA · Rv0007 — disagrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT0005) exponential phase: operon of 6, Rv0002 · Rv0003 · Rv0004 · Rv0005 · Rv0006 · Rv0007 (coverage 100.91)
stationary phase: operon of 2, Rv0005 · Rv0006 (coverage 40.86) — agrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Transcriptional regulation (signed TRN: ChIP-seq + TFOE)

Regulated by (2 TF) Rv0023 (represses) · Rv1049 (activates)

Regulatory edges from the ISB signed transcriptional regulatory network (TF ChIP-seq binding, Minch 2015 + TF-overexpression response, Rustad 2014). An edge is regulatory evidence (binding and/or expression change), not necessarily direct. For a "hypothetical", membership in a known regulon (e.g. DosR dormancy, PhoP virulence) is a physiological-context lead, not a function.

Condition: Condition-blind by construction. These edges come from transcription-factor OVEREXPRESSION in a single laboratory condition, so a listed regulator is not a claim that it governs this gene in every circumstance. Measured counter-examples exist within this atlas (see Rv2516c, where the DosR regulon collapses under moxifloxacin while the gene itself rises). Read a regulator as 'capable of shifting this gene', and look for the condition before building a hypothesis on it.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: gyrA (DNA gyrase subunit A), high confidence (score 1000, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence). The pair rests on an interaction measured in M. tuberculosis itself (own experimental score 900): a measured association in this organism, as opposed to one carried over from other proteomes.

Showing the 15 strongest of this gene's 174 partners at medium confidence (47 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. Of the 174 partners, 1 rest on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv0006 gyrA measured in Mtb DNA gyrase subunit A 999 1000 ctx neighborhood:830 cooccurence:773 coexpression:942 experimental:981 textmining:989
Rv3361c mfpA exp (transferred) hypothetical protein 997 997 experimental:997
Rv0730 exp (transferred) GCN5-like N-acetyltransferase 956 951 coexpression:726 experimental:818
Rv0003 recF DNA replication/repair protein RecF 975 900 ctx neighborhood:727 coexpression:650 textmining:769
Rv0002 dnaN DNA polymerase III subunit beta 952 854 ctx neighborhood:714 coexpression:446 textmining:685
Rv0004 hypothetical protein 797 785 ctx neighborhood:727
Rv0007 membrane protein 772 759 ctx neighborhood:743
Rv2373c dnaJ2 chaperone protein DnaJ 836 686 ctx cooccurence:596 textmining:500
Rv2793c truB exp (transferred) tRNA pseudouridine synthase B 689 675 experimental:412
Rv1650 pheT phenylalanine--tRNA ligase subunit beta 820 658 ctx neighborhood:473 textmining:496
Rv3769 hypothetical protein 652 615
Rv2731 hypothetical protein 652 615
Rv2922c smc chromosome partition protein Smc 652 615
Rv2614c thrS threonine--tRNA ligase 655 596 ctx cooccurence:567
Rv0352 dnaJ1 chaperone protein DnaJ 793 589 ctx cooccurence:472 textmining:519

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: DNA gyrase subunit B
  • MTBC0 PGAP product: DNA topoisomerase (ATP-hydrolyzing) subunit B
  • Pfam (hmmscan --cut_ga): HATPase_c PF02518.32 (E=3e-15), DNA_gyraseB PF00204.32 (E=2e-63), Toprim PF01751.29 (E=5e-17), DNA_gyraseB_C PF00986.27 (E=3e-26)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_214519.2)
  • Domains: Pfam-A via hmmscan --cut_ga — HATPase_c (PF02518.32), DNA_gyraseB (PF00204.32), Toprim (PF01751.29), DNA_gyraseB_C (PF00986.27)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG0187
  • Curated reference: UniProt P9WG45 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 89.0)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 174 functional partner(s); context anchor gyrA
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Transcriptional regulation: ISB signed TRN — TF ChIP-seq (Minch et al. 2015, doi:10.1038/ncomms6829) + TF overexpression (Rustad et al. 2014, doi:10.1186/gb-2014-15-11-502)
  • Drug resistance: consolidated catalogue, WHO 2nd ed. 2023 (9789240082410) + tb-profiler; only the resistance-associated tier (grade 1–2) is surfaced
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_000005|Rv0005|gyrB
MAAQKKKAQDEYGAASITILEGLEAVRKRPGMYIGSTGERGLHHLIWEVVDNAVDEAMAGYATTVNVVLLEDGGVEVADDGRGIPVATHASGIPTVDVVMTQLHAGGKFDSDAYAISGGLHGVGVSVVNALSTRLEVEIKRDGYEWSQVYEKSEPLGLKQGAPTKKTGSTVRFWADPAVFETTEYDFETVARRLQEMAFLNKGLTINLTDERVTQDEVVDEVVSDVAEAPKSASERAAESTAPHKVKSRTFHYPGGLVDFVKHINRTKNAIHSSIVDFSGKGTGHEVEIAMQWNAGYSESVHTFANTINTHEGGTHEEGFRSALTSVVNKYAKDRKLLKDKDPNLTGDDIREGLAAVISVKVSEPQFEGQTKTKLGNTEVKSFVQKVCNEQLTHWFEANPTDAKVVVNKAVSSAQARIAARKARELVRRKSATDIGGLPGKLADCRSTDPRKSELYVVEGDSAGGSAKSGRDSMFQAILPLRGKIINVEKARIDRVLKNTEVQAIITALGTGIHDEFDIGKLRYHKIVLMADADVDGQHISTLLLTLLFRFMRPLIENGHVFLAQPPLYKLKWQRSDPEFAYSDRERDGLLEAGLKAGKKINKEDGIQRYKGLGEMDAKELWETTMDPSVRVLRQVTLDDAAAADELFSILMGEDVDARRSFITRNAKDVRFLDV